Answers are grounded in this paper and cite their sources.
The use of implantable ventricular assist devices for the treatment of advanced, decompensated heart failure as a bridge to heart transplantation has experienced considerable evolution over the past decade. Improvements in the management and prevention of serious adverse events, and introduction of new continuous-flow rotary pumps that are smaller, more durable, and associated with fewer serious adverse advents has expanded the use of this therapy to a larger population of patients for bridge to transplant indication.
No takes yet. Share an insight, caveat, or question.
Aggarwal et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: